Marker Therapeutics (NASDAQ:MRKR) Price Target Raised to $19.00 at LADENBURG THALM/SH SH

Marker Therapeutics (NASDAQ:MRKR) had its price target increased by investment analysts at LADENBURG THALM/SH SH from $11.00 to $19.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s price target points to a potential upside of 318.50% from the company’s current price.

Marker Therapeutics Stock Performance

Shares of NASDAQ MRKR opened at $4.54 on Monday. Marker Therapeutics has a fifty-two week low of $2.40 and a fifty-two week high of $6.16. The business has a 50 day moving average price of $3.09 and a two-hundred day moving average price of $3.97.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.25) earnings per share for the quarter. Marker Therapeutics had a negative net margin of 278.27% and a negative return on equity of 78.91%. The business had revenue of $1.17 million for the quarter. As a group, sell-side analysts expect that Marker Therapeutics will post -1.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Marker Therapeutics stock. Wedbush Securities Inc. lifted its position in Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 69,500 shares of the company’s stock after acquiring an additional 24,000 shares during the quarter. Wedbush Securities Inc. owned 0.78% of Marker Therapeutics worth $377,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.